Be the first person to write a business review for Omrix Biopharmaceuticals, Inc.

Oncolytics Biotech is bringing in viral mercenaries to fight in the battle against cancer. The company is developing REOLYSIN, a therapy that utilizes a Respiratory Enteric Orphan virus (or reovirus) to treat a variety of advanced cancer tumors, both alone and in combination with other drug therapies, as well as radiation and chemotherapy. The Canadian company is collaborating with the US-based National Cancer Institute to conduct clinical trials of the treatment. It also conducts trials in Canada and the UK. Oncolytics' technologies are based on discoveries made by the Department of Microbiology and Infectious Diseases at the University of Calgary.

Oncothyreon Inc. was founded in 1985 and is headquartered in Bellevue, Washington. Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. The Company’s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Oncothyreon’s lead product candidate is Stimuvax, which is a cancer vaccine in Phase III development for non-small cell lung cancer (NSCLC). Oncothyreon has an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax. Its pipeline of product candidates is consisted of cancer vaccines and small molecule candidates. The Company’s wholly owned subsidiaries include Oncothyreon Canada Inc., Biomira Management Inc., ProlX Pharmaceuticals Corporation, Biomira International Inc., Biomira BV and Oncothyreon Luxembourg.

Ondine Biopharma wants to offer an alternative to antibiotics for treating infections. The company is focused on the development and commercialization of its patented light-activated technology, called photodynamic disinfection, as a therapy for bacterial, fungal, and viral infections. Ondine Biopharma is developing a nasal system called MRSAid that incorporates hardware and photosensitizers to help treat often deadly hospital-acquired pathogens, such as staph infections. If commercialized, that product would give the company entry into the hospital infection control market.

Cancer is the only target of Onyvax. The development-stage biotech aims to come up with novel immunotherapies to treat advanced prostate and other forms of cancer. Onyvax's therapeutic cancer vaccines combine inactivated cell lines that create immune responses to tumor targets. The firm has several products in clinical trials, including lead candidate Onyvax-P, a cell vaccine that could treat hormone-resistant prostate cancer. While most of the company's candidates target specific types of cancer, its Onyvax-105 uses human monoclonal antibodies to attack the CD55 molecule, giving the therapy potential for treating many types of cancer.

Onyx Pharmaceuticals was founded in 1992 and is headquartered in Emeryville, California. Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally. Its lead product includes Nexavar (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in tumor cell proliferation and angiogenesis. This product is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals. The company is also conducting various ongoing trials on Nexavar for conditions, such as non-small cell lung cancer, melanoma, breast cancer, and other cancers. It also develops ONX 0801, an oncology compound in preclinical development stage, under a development and license agreement with BTG International Limited. In addition, Onyx Pharmaceuticals, through a development collaboration, option, and license agreement with S*BIO Pte Ltd, owns options to license the rights of ONX 0803 and ONX 0805. ONX 0803 is an orally available, potent, and selective inhibitor of JAK2; and ONX 0805 is a JAK2 inhibitor. Further, the company has a research and development collaboration agreement with Warner-Lambert Company to discover and commercialize small molecule drugs that restore the control of, or otherwise intervene in, the misregulated cell cycle in tumor cells.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.